Chronic Kidney Disease News, Treatment Studies | CKD Clinical Research

Chronic Kidney Disease (CKD)


Phosphate Binders Cut Mortality, Up ESRD Risk

Potassium Binder May Enable Optimal RAASi Use in CKD

In a study, 87% of hyperkalemic patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy were able to continue or increase their RAASi doses while concurrently taking sodium zirconium cyclosilicate.
Next post in Chronic Kidney Disease (CKD)